Type 2 innate lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity and requires inducible T-cell costimulator–inducible T-cell costimulator ligand interaction - 27/09/17
Abstract |
Background |
Atopic diseases, including asthma, exacerbate type 2 immune responses and involve a number of immune cell types, including regulatory T (Treg) cells and the emerging type 2 innate lymphoid cells (ILC2s). Although ILC2s are potent producers of type 2 cytokines, the regulation of ILC2 activation and function is not well understood.
Objective |
In the present study, for the first time, we evaluate how Treg cells interact with pulmonary ILC2s and control their function.
Methods |
ILC2s and Treg cells were evaluated by using in vitro suppression assays, cell-contact assays, and gene expression panels. Also, human ILC2s and Treg cells were adoptively transferred into NOD SCID γC-deficient mice, which were given isotype or anti–inducible T-cell costimulator ligand (ICOSL) antibodies and then challenged with IL-33 and assessed for airway hyperreactivity.
Results |
We show that induced Treg cells, but not natural Treg cells, effectively suppress the production of the ILC2-driven proinflammatory cytokines IL-5 and IL-13 both in vitro and in vivo. Mechanistically, our data reveal the necessity of inducible T-cell costimulator (ICOS)–ICOS ligand cell contact for Treg cell–mediated ILC2 suppression alongside the suppressive cytokines TGF-β and IL-10. Using a translational approach, we then demonstrate that human induced Treg cells suppress syngeneic human ILC2s through ICOSL to control airway inflammation in a humanized ILC2 mouse model.
Conclusion |
These findings suggest that peripheral expansion of induced Treg cells can serve as a promising therapeutic target against ILC2-dependent asthma.
Le texte complet de cet article est disponible en PDF.Key words : Type 2 innate lymphoid cells, regulatory T cells, IL-5, IL-13, asthma, airway hyperreactivity, inducible T-cell costimulator, inducible T-cell costimulator ligand
Abbreviations used : AHR, BAL, CRTH2, FACS, Foxp3, GFP, ICOS, ICOSL, ILC2, iTreg, LAP, NSG, nTreg, PE, rh, Teff, Treg, TSLP, USC
Plan
| The studies described in this article were financially supported by National Institutes of Health Public Health Service grants R01ES 021801, R01ES025786, R21AI109059 and R21 ES 024707 (to O.A.) and NIAID P01 AI 056299 (to G.F. and A.S.). |
|
| Disclosure of potential conflict of interest: J. L. Aron, H. Maazi, G. J. Freeman, A. H. Sharpe, O. Akbari's institutions have all received a grant from the National Institutes of Health. The rest of the authors declare that they have no relevant conflict of interest. |
Vol 139 - N° 5
P. 1468 - mai 2017 Retour au numéro
Article précédent
- Pathways to limit group 2 innate lymphoid cell activation
- Taylor A. Doherty, David H. Broide
- The nasal methylome and childhood atopic asthma
- Ivana V. Yang, Brent S. Pedersen, Andrew H. Liu, George T. O'Connor, Dinesh Pillai, Meyer Kattan, Rana Tawil Misiak, Rebecca Gruchalla, Stanley J. Szefler, Gurjit K. Khurana Hershey, Carolyn Kercsmar, Adam Richards, Allen D. Stevens, Christena A. Kolakowski, Melanie Makhija, Christine A. Sorkness, Rebecca Z. Krouse, Cynthia Visness, Elizabeth J. Davidson, Corinne E. Hennessy, Richard J. Martin, Alkis Togias, William W. Busse, David A. Schwartz
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?